Predicting Tumor Volume in Radical Prostatectomy Specimens From Patients With Prostate Cancer

American Journal of Clinical Pathology

Volumn 120, Issue 3, 2003, Pages 386-391

  Eichelberger, Lori E ^a   Koch, Michael O ^a   Daggy, Joanne K ^a   Ulbright, Thomas M ^a   Eble, John N ^a   Cheng, Liang ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neoplasm; Prostate; Prostatectomy; Tumor length; Tumor staging; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CALCULATION; CANCER INVASION; CANCER STAGING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 85047688844     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/82U1089XLQGKMMN1     Document Type: Article

References (37)

1. Bostwick DG, Graham SD Jr, Napalkov P, et al. Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology. 1993;41:403-411.
2. Renshaw AA. Correlation of gross morphologic features with histologic features in radical prostatectomy specimens. Am J Clin Pathol. 1998;110:38-42.
3. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 1998;90:233-237.
4. Greene DR, Egawa S, Neerhut G, et al. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol. 1991;146:1069-1076.
5. Srigley JR, Amin MB, Bostwick DG, et al. Update protocols for the examination of specimens from patients with carcinomas of the prostate gland. Arch Pathol Lab Med. 2000;124:1034-1039.
6. Bostwick DG, Grignon DJ, Hammond EH, et al. Prognostic factors in prostate cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124:995-1000.
7. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of resected prostate carcinomas. Am J Clin Pathol. 1996;105:667-670.
8. Cantrell BB, DeKlerk DP, Eggleston JC, et al. Pathological factors that influence prognosis in state A prostatic cancer: the influence of extent versus grade. J Urol. 1980;125:516-520.
9. Humphrey PA, Vollmer RT. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol. 1997;10:326-333.
10. Jones EC. Resection margin status in radical retropubic prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol. 1990;144:89-93.
11. Renshaw AA, Chang H, D'Amico AV. Estimation of tumor volume in radical prostatectomy specimens in routine clinical practice. Am J Clin Pathol. 1997;107:704-708.
12. Humphrey PA, Vollmer RT Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol. 1990;21:799-804.
13. Lemer SE, Seay TM, Blute ML, et al. Prostate-specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol. 1996;155:821-826.
14. Epstein JI, Carmichael M, Partin AW, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? a multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol. 1993;149:1478-1481.
15. McNeal JE, Kindrachuk RA, Freiha FS, et al. Patterns of progression in prostate cancer. Lancet. 1986;1:60-63.
16. Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate-specific antigen based screening. J Urol. 1996;155:816-820.
17. Babaian RJ, Troncoso P, Steelhammer LC, et al. Tumor volume and prostate-specific antigen: implications for early detection and defining a window of curability. J Urol. 1995;154:1808-1812.
18. Cheng L, Darson MF, Bergstralh EJ, et al. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer. 1999;86:1775-1782.
19. Cheng L, Slezak J, Bergstralh EJ, et al. Preoperative prediction of surgical margin status in prostate cancer patients treated by radical prostatectomy. J Clin Oncol. 2000;18:2862-2868.
20. Hong H, Koch MO, Foster RS, et al. Anatomic distribution of periprostatic adipose tissue: a mapping study of 100 radical prostatectomy specimens. Cancer. 2003;97:1639-1643.
21. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Semin Surg Oncol. 1994;10:60-72.
22. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol. 1997;28:143-148.
23. Dugan JA, Bostwick DG, Myers RP, et al. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 1996;275:288-294.
24. Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998;22:1491-1500.
25. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical stage. J Urol. 1974;111:58-64.
26. Bostwick DG. Neoplasms of the prostate. In: Bostwick DG, Eble JN, eds. Urologic Surgical Pathology. St Louis, MO: Mosby; 1997:343-422.
27. Fleming ID, Cooper JS, Henson DE, et al (American Joint Committee on Cancer), eds. Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997.
28. Stamey T, McNeal J, Freiha F, et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol. 1988;139:1235-1241.
29. Stamey T, McNeal J, Yemoto C, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395-1400.
30. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate. 2001;49:48-57.
31. Ohori M, Wheeler TM, Dunn JK, et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994;152:1714-1720.
32. Goto Y, Ohori M, Arakawa A, et al. Distinguishing clinically important from unimportant prostate cancer before treatment. J Urol. 1996;156:1059-1063.
33. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993;71:933-938.
34. Renshaw AA, Richie JO, Loughlin KR, et al. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer. 1998;83:748-752.
35. Renshaw AA, Richie JP, Loughlin KR, et al. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Am J Clin Pathol. 1999;111:641-644.
36. Noguchi M, Stamey TA, McNeal JE, et al. Assessment of morphometric measurements of prostate carcinoma volume. Cancer. 2000;89:1056-1064.
37. Carvalhal GF, Humphrey PA, Phataraporn T, et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000;89:1308-1314.